FaceScan for Measuring Visual Acuity

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Mayo Clinic

Disqualifiers: Under 18, unable to consent

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The purpose of this research is to validate and determine the accuracy of the experimental device when measuring visual acuity versus our standard visual acuity measurements and to gather voice recordings of letters to help build a special system that recognizes spoken letters.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the FaceScan treatment for measuring visual acuity?

The research does not provide direct evidence about FaceScan, but it highlights the effectiveness of digital tools like the EyeChart app and Easee web-based tool for measuring visual acuity, suggesting that technology-based methods can be accurate and useful in assessing vision.¹ ² ³ ⁴ ⁵

How is the FaceScan treatment for measuring visual acuity different from other treatments?

FaceScan is unique because it likely uses facial recognition technology to assess visual acuity, which is different from traditional methods like eye charts or apps that require direct interaction. This approach could offer a more seamless and non-invasive way to measure vision, potentially making it easier for patients who have difficulty with standard tests.¹ ⁶ ⁷ ⁸ ⁹

Research Team

Antonio Forte, MD

Principal Investigator

Mayo Clinic

Eligibility Criteria

This trial is for adults over 18 years old who visit the Ophthalmology Clinic and can give consent. It's not specified who cannot participate, so it seems open to all adult patients needing visual acuity measurements.

Inclusion Criteria

Willing and able to provide consent.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Participants undergo a baseline ophthalmological examination including a digital visual acuity test with the FaceScan device

1 day

1 visit (in-person)

Follow-up

Participants are monitored for any immediate reactions or issues post-assessment

1 week

Treatment Details

Interventions

FaceScan

Trial Overview The study is testing a new digital device called FaceScan to check if it measures eyesight as well as standard methods. Participants will also help by providing voice recordings of letters for a speech recognition system.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Digital Visual Acuity TestExperimental Treatment1 Intervention

Subjects for an ophthalmological examination that includes a visual acuity examination at Mayo Clinic in Florida have a digital visual acuity test conducted with the FaceScan device.